re: Ann: Clinuvel commences US Phase III tria... It's about as safe a bet for approval in Europe as you're going to get except for a drug that is attempting to get generic approval.
The downside is:
1 - we don't know when European regulators will make a decision
2 - the market still doesn't appear to be too jazzed about EPP
3 - if the overall markets get slammed by the stuff going on in Europe (Greece, etc.), then Australian markets will suffer as well
4 - the company's cash position, which I still suspect is keeping a lot of people on the sidelines
JMO
Ann: Clinuvel commences US Phase III trial of SCE, page-9
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.42 |
Change
-0.300(2.04%) |
Mkt cap ! $728.6M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.00 | $14.40 | $417.8K | 28.70K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 5471 | $14.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.42 | 73 | 8 |
View Market Depth
| Last trade - 13.33pm 09/09/2024 (20 minute delay) ? |
| CUV (ASX) Chart |